Cetuximab is a chimeric monoclonal antibody designed to target the epidermal growth factor receptor (EGFR). It works by blocking EGFR-mediated signaling pathways, which are responsible for tumor cell growth and survival.
Indications:
Metastatic colorectal cancer (KRAS wild-type, EGFR-expressing)
Head and neck squamous cell carcinoma
Used in combination with chemotherapy or as monotherapy in certain cases
Dosage Form:
100mg/20ml vial (Injection, r-DNA Origin)
Mode of Administration:
Intravenous infusion under the supervision of an oncology specialist
Key Benefits:
✅ Inhibits tumor cell proliferation
✅ Enhances chemotherapy and radiotherapy response
✅ Improves overall survival in select cancers
Precautions:
⚠️ Must be administered in a hospital or oncology center
⚠️ Risk of infusion-related reactions
⚠️ Monitor for hypomagnesemia, rash, and pulmonary toxicity
⚠️ Not recommended for KRAS-mutated colorectal cancer
Storage:
Store in a refrigerator (2°C – 8°C). Do not freeze. Protect from light.
